Sodium thiosulfate for prevention of hearing loss in children receiving cisplatin chemotherapy
NIHR HSRIC
Record ID 32016000330
English
Authors' objectives:
Sodium thiosulfate is intended to be used to prevent hearing loss in children who receive cisplatin chemotherapy. It inactivates platinum complexes by binding electrophilic platinium with thiol, thus forming a covalent complex that is not cytotoxic and can be excreted rapidly. Sodium thiosulfate does not currently have Marketing Authorisation in the EU for any indication.
Cancer in children (aged 0-14 years) is rare compared with the adult population, accounting for less than 1% of all cancers. Cisplatin is a widely-used chemotherapeutic agent and is standard of care for a variety of paediatric malignancies. All children who receive cisplatin are at risk of cisplatin-induced hearing loss, and it occurs in at least 60% of treated patients. Hearing loss is likely to delay speech and language development in children and can have a significant impact on school performance and psychosocial functioning.
There are currently no treatment options available to prevent hearing loss in children receiving cisplatin chemotherapy. Sodium thiosulfate is currently in phase III clinical trials investigating its effect on hearing loss when administered alongside cisplatin chemotherapy. These trials are expected to complete in late 2015 and late 2017.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.hsric.nihr.ac.uk/topics/sodium-thiosulfate-for-prevention-of-hearing-loss-in-children-receiving-cisplatin-chemotherapy/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Child
- Cisplatin
- Deafness
- Hearing Loss
- Thiosulfates
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.